US 12226456
Nasal powder formulation for treatment of hypoglycemia
granted A61KA61K31/724A61K38/26
Quick answer
US patent 12226456 (Nasal powder formulation for treatment of hypoglycemia) held by Amphastar Pharmaceuticals, Inc. expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Amphastar Pharmaceuticals, Inc.
- Grant date
- Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K31/724, A61K38/26, A61K47/12, A61K47/24